News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,760 Results
Type
Article (42334)
Company Profile (436)
Press Release (671990)
Multimedia
Podcasts (78)
Webinars (13)
Section
Business (208753)
Career Advice (2021)
Deals (36009)
Drug Delivery (104)
Drug Development (83582)
Employer Resources (173)
FDA (16434)
Job Trends (15099)
News (352819)
Policy (33086)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (87)
Alliances (50963)
ALS (94)
Alzheimer's disease (1431)
Antibody-drug conjugate (ADC) (139)
Approvals (16424)
Artificial intelligence (270)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (83)
Brain cancer (27)
Breast cancer (287)
Cancer (2324)
Cardiovascular disease (186)
Career advice (1689)
Career pathing (30)
CAR-T (158)
Cell therapy (446)
Cervical cancer (19)
Clinical research (67788)
Collaboration (877)
Company closure (1)
Compensation (541)
Complete response letters (24)
COVID-19 (2648)
CRISPR (45)
C-suite (253)
Cystic fibrosis (105)
Data (2242)
Decentralized trials (2)
Denatured (28)
Depression (51)
Diabetes (275)
Diagnostics (6429)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (108)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87884)
Editorial (41)
Employer branding (21)
Employer resources (147)
Events (115989)
Executive appointments (743)
FDA (17718)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (785)
Gene editing (113)
Generative AI (20)
Gene therapy (329)
GLP-1 (749)
Government (4505)
Grass and pollen (4)
Guidances (67)
Healthcare (19146)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (30)
Infectious disease (2793)
Inflammatory bowel disease (144)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (311)
IPO (16790)
IRA (43)
Job creations (3701)
Job search strategy (1434)
Kidney cancer (10)
Labor market (38)
Layoffs (498)
Leadership (18)
Legal (7986)
Liver cancer (76)
Lung cancer (328)
Lymphoma (156)
Machine learning (7)
Management (58)
Manufacturing (314)
MASH (70)
Medical device (13528)
Medtech (13533)
Mergers & acquisitions (19760)
Metabolic disorders (721)
Multiple sclerosis (82)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2005)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (39)
Obesity (387)
Opinion (223)
Ovarian cancer (77)
Pain (91)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (236)
Patient recruitment (113)
Peanut (47)
People (58689)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21303)
Phase II (29910)
Phase III (22116)
Pipeline (1228)
Policy (148)
Postmarket research (2601)
Preclinical (9138)
Press Release (67)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (404)
Real estate (6015)
Recruiting (66)
Regulatory (22751)
Reports (46)
Research institute (2416)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (77)
Series A (140)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3762)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (40)
The Weekly (48)
Vaccines (709)
Venture capitalists (43)
Weight loss (255)
Women's health (37)
Worklife (17)
Date
Last 7 days (913)
Last 30 days (2539)
Last 365 days (33607)
2025 (11043)
2024 (36301)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (58)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (39262)
Australia (6532)
California (6274)
Canada (2031)
China (536)
Colorado (273)
Connecticut (288)
Delaware (151)
Europe (85819)
Florida (916)
Georgia (207)
Idaho (57)
Illinois (555)
India (25)
Indiana (312)
Iowa (12)
Japan (164)
Kansas (107)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (915)
Massachusetts (4759)
Michigan (222)
Minnesota (398)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1765)
New Mexico (30)
New York (1770)
North Carolina (1036)
North Dakota (8)
Northern California (2715)
Ohio (207)
Oklahoma (14)
Oregon (38)
Pennsylvania (1395)
Puerto Rico (12)
Rhode Island (34)
South America (1110)
South Carolina (23)
South Dakota (1)
Southern California (2344)
Tennessee (101)
Texas (927)
United States (23748)
Utah (183)
Virginia (151)
Washington D.C. (64)
Washington State (575)
West Virginia (3)
Wisconsin (55)
714,760 Results for "evolveimmune therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EvolveImmune Therapeutics Announces Translational Research Collaboration to Evaluate Expression of Novel Tumor Target in Muscle-Invasive Bladder Cancer
April 8, 2025
·
2 min read
Press Releases
EvolveImmune Appoints Kristen M. Hege, M.D. to Its Board of Directors
February 12, 2025
·
3 min read
Press Releases
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer Biotherapeutics
October 31, 2024
·
5 min read
Pharm Country
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
EvolveImmune Therapeutics provided a corporate and program update related to the advancement of its pipeline of first-in-category precision immuno-oncology agents.
December 13, 2023
·
4 min read
Press Releases
EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 11, 2024
·
6 min read
Press Releases
EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 24, 2024
·
5 min read
Business
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, announced a new research partnership with Michael Dustin, Ph.D., to evaluate the molecular mechanism of action of EvolveImmune’s proprietary costimulatory T cell engager platform, known as EVOLVE.
June 14, 2023
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
EvolveImmune Therapeutics to Present New Preclinical and Translational Data Highlighting Precision Medicine Potential of its Novel Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
EvolveImmune Therapeutics will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held November 1-5, 2023, in San Diego, California.
October 18, 2023
·
4 min read
Drug Development
EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
EvolveImmune Therapeutics announced that new preclinical and translational data highlighting EV-104 and EV-106, two programs utilizing EVOLVE, the company’s proprietary costimulatory T cell engager platform were presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer.
November 6, 2023
·
6 min read
1 of 71,476
Next
